China National Medicines Corporation Ltd.

XSSC:600511 Stock Report

Market Cap: CN¥24.3b

China National Medicines Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Guotao Tian

Chief executive officer

CN¥2.6m

Total compensation

CEO salary percentagen/a
CEO tenure2.8yrs
CEO ownershipn/a
Management average tenure2.1yrs
Board average tenure2.8yrs

Recent management updates

Recent updates

CEO

Guotao Tian (53 yo)

2.8yrs

Tenure

CN¥2,550,000

Compensation

Mr. Guotao Tian is GM & Director of China National Medicines Corporation Ltd. from April 07, 2022.

Leadership Team

NamePositionTenureCompensationOwnership
Guotao Tian
GM & Director2.8yrsCN¥2.55mno data
Fei Chen
Chief Financial Officer1.3yrsCN¥191.30kno data
Lichun Luo
Board Secretary2.8yrsCN¥1.15mno data
Zhang Ting
Deputy Secretary of the Party Committeeno dataCN¥371.90kno data

2.1yrs

Average Tenure

46yo

Average Age

Experienced Management: 600511's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Guotao Tian
GM & Director2.8yrsCN¥2.55mno data
Xiuchang Jiang
Chairman13.9yrsno datano data
Yong Liu
Director13.2yrsno datano data
Jingyun Liu
Chairman of the Supervisory Board13.2yrsno datano data
Luwen Shi
Independent Director2.8yrsCN¥200.00kno data
Xingxi Yu
Independent Director2.8yrsCN¥200.00kno data
Deyong Wen
Director5.8yrsno datano data
Xin Jiang
Director2.8yrsCN¥2.55mno data
Xiaojuan Li
Director2.8yrsno datano data
Kai Lu
Supervisor2.8yrsno datano data

2.8yrs

Average Tenure

53yo

Average Age

Experienced Board: 600511's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 07:39
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

China National Medicines Corporation Ltd. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Yanyin ZhuChina International Capital Corporation Limited
Ying LuoChina Merchants Securities Co. Ltd.